# OnCo record paper-pacific-nejm-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-pacific-nejm-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-pacific-nejm-2017" ;
  schema:name "PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer"@en ;
  schema:description "Giving the immunotherapy durvalumab for a year after chemoradiotherapy for unresectable stage III lung cancer tripled the time to progression and raised five-year survival from about a third to over 40%."@en ;
  schema:url <https://onco.cc/key-papers/paper-pacific-nejm-2017/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1709937>, <https://doi.org/10.1056/NEJMoa1809697>, <https://clinicaltrials.gov/study/NCT02125461> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1709937> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Antonia SJ, Villegas A, Daniel D, et al." ;
  onco:related <https://onco.cc/roadmaps/lung-cancer-evidence-roadmap/>, <https://onco.cc/key-papers/paper-spigel-pacific-five-year-survival-jco-2022/>, <https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/>, <https://onco.cc/terms/standard-of-care/>, <https://onco.cc/terms/irae/> ;
  onco:people <https://onco.cc/people/cho-byoung-chul/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .